Key facts
- Addyi’s last known valuation is $1.4B (Oct 2015).
- It has raised $70.1M; the latest was Later Stage VC ($45.6M) in Dec 2024.
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for Addyi
- ·The full record, as it builds
Funding rounds
No funding rounds for Addyi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Addyi
Operator of a medical company intended for the treatment of female sexual dysfunction. The company offers a drug that helps in the treatment of acquired extremely low libido, enabling pre-menopausal women to reduce distress from the loss of sexual desire and increase the number of satisfying sexual events.
- Sector
- Healthcare
- HQ
- Raleigh, NC, United States
- Founded
- 2011
- Employees
- 31
- Website
- addyi.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Addyi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Addyi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Addyi in its N-PORT filings yet. We sweep new filings monthly.